Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…inhibitors (4), tumour necrosis factor (TNF) inhibitors (1) and tocilizumab (1). Pooled analysis showed no significant overall change in FV…
…ded to confirm these findings about safety and effectiveness of talquetamab.Conflict of Interest No conflict of interest…
…arthritis was the most frequent diagnosis (30%).Drugs involved: adalimumab (35%), etanercept (25%), certolizumab (8%), belimumab (6%), ixe…
…everity, and management of irAEs in melanoma patients receiving ipilimumab–nivolumab therapy.Material and Methods A retrospective observat…
….2%; grade 2: 77.8%]; CAR-T: 90% [grade 1: 65%; grade 2: 25%]). Tocilizumab was used less frequently for BsAb-related CRS (77.8% vs 100%). …
…mplications.Conclusion and Relevance In this real-world cohort, axi-cel showed predictable but significant toxicity, including universa…
… refractory to multiple therapies, highlighting the response to rituximab. Prior reports support the benefit of rituximab in SLE-associat…
…ory values. The patient was then discharged on a stable dose of ruxolitinib, anakinra and prednisone. This case illustrates the therapeutic…
…as conducted in US and similar trends were observed.Conclusions FL115 is the first IL-15 superagonist reporting PR as monotherapy in …
… high-affinity FDA-approved inhibitors for IL6R and EGFR (e.g., tocilizumab and erlotinib), as well as PAM analogs targeting mGluR7. Logic …
…eived conditioning with either fludarabine/cyclophosphamide, or bendamustine, followed by CD4CAR in a 3+3 dose-escalation design. Safety and…
…umab was used in one relapsing case with no effect. Gabapentin, duloxetine, diazepam, baclofen, tizanidine and cannabinoid oils were helpf…